Retatrutide, a GIP, GLP1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, doubleblind, placebo and activecontrolled, parallelgroup, phase 2 trial conducted in the USA
Taking it every other week is not recommended, as it may not provide the consistent results needed for optimal weight loss and metabolic control
However, youll need to monitor your tolerance closely or abstain altogether if you have certain conditions
They also look at methylmalonic acid (MMA), a substance related to B12, and homocysteine levels, which can indicate low B12
The release of exenatide into the general circulation occurs in three stages
Pioglitazone for secondary stroke prevention: A systematic review and Meta-Analysis